GILEAD SCIENCES, INC. (NASDAQ: GILD) Chief Medical Officer Berger Dietmar’s option exercise left him with 19,785 shares on Sep. 10, 2026. The transaction represented about 2.7% of his resulting shareholding. A separate transaction on the same date reduced his reported holding to 19,522 shares. …
Few tickers illustrate the fate of the pandemic-era cannabidiol boom as starkly as Hempfusion Wellness Inc. (OTC:CBDHF). Once a well-distributed U.S. CBD and wellnessBrandwith shelves in thousands of retail stores, the company now trades at a fraction of a cent on the over-the-counter market, …
GILEAD SCIENCES, INC. (NASDAQ: GILD) CEO Daniel Patrick O’Day exercised options for 8,780 shares on 10 September 2026, leaving him with 585,913 shares after the transaction. The filing also records a forfeiture of shares and an exercise involving derivative securities.
GILEAD SCIENCES, INC. (NASDAQ: GILD) CFO Andrew D. Dickinson exercised options for 2,797 shares on September 10, 2026. The transaction left Dickinson with 168,443 shares, while a separate entry recorded the forfeiture of 1,347 shares at $144.81 per share.
Conexeu Sciences Inc has quietly become one of the more distinctive biotechnology newcomers on theNasdaqthis year, a preclinical regenerative-medicine story that only reached public markets in 2026. Trading under the ticker CNXU, shares closed up 4.94% at $4.46 at last closing, putting technical levels …
Health Catalyst, Inc. (NASDAQ: HCAT) CEO Albert Benjamin forfeited 35,244 shares at $1.67 per share on Sep. 10, 2026. The transaction represented about 2.5% of his prior share holding.
A quietTrading sessioncan mask a busy year. Hemab Therapeutics Holdings, whose shares closed down 1.20% at $39.40 at last closing, spent the spring and summer of 2026 building a clinical dossier around rare and serious bleeding disorders while its stock more than doubled from …
There is penny-stock territory, and then there is what Bellrock Brands (OTC:DXBRF) has become. The cannabis products company changes hands at a fraction of a cent, a price that leaves its entire public equity valued at little more than pocket change. No independently verifiable …
Eikon Therapeutics, Inc. has long been one of biotechnology's better-known platform stories, and its move ontoNasdaqunder the ticker EIKN has given public investors a way to follow it. Shares closed down 2.93% at $8.94 at last closing even as the company signals a step …
Few tickers illustrate the mechanics of the sub-penny market quite like Energy Resource Abundance, Inc. (OTC:ERAO). Trading at a fraction of a cent, shares closed up 44% at last closing, an eye-catching figure that sounds dramatic, yet at these price levels a move of …